Protein Sciences Corporation

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Protein Sciences Corporation sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials none currently recruiting 12 completed top decile by trial count

Protein Sciences Corporation: 12 sponsored US clinical trials, none currently recruiting.

Protein Sciences Corporation sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 12 completed. 6 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Influenza, with 5 trials.

Top-decile sponsor footprint

Protein Sciences Corporation ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

12 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

12 total, page 1 of 1

COMPLETED

Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults

NCT02600585

COMPLETED Phase 1

Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older

NCT02464163

COMPLETED Phase 3

Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age

NCT02290509

COMPLETED Phase 3

Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age

NCT02285998

COMPLETED Phase 3

Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)

NCT01959945

COMPLETED Phase 3

Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age

NCT01825200

COMPLETED Phase 1

Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults

NCT01612000

COMPLETED Phase 1

Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults

NCT01147068

COMPLETED Phase 3

Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV

NCT00539864

COMPLETED Phase 1

Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics

NCT00336453

COMPLETED Phase 3

Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults

NCT00395174

COMPLETED Phase 2

Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults

NCT00328107

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 1
Phase 3 6

Therapeutic Areas

How the Protein Sciences Corporation archive is shaped

12 indexed studies, none listed as recruiting (0% open); 12 completed (100%).

Phase mix: 6 late (III/IV) vs 5 early (I/II) (balanced across stages).

Top condition: Influenza (5 trials), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Protein Sciences Corporation: archived-pipeline peers nationwide

Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Protein Sciences Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20% Total trials Recruiting share Protein Sciences CorporationAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.Angiodynamics10xBio22nd Century Group23andMe3-C Institute for Social Development
Protein Sciences Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Protein Sciences Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Protein Sciences Corporation page

12 registered trials is a research-attention snapshot, not an endorsement of Protein Sciences Corporation or any single study.

  • None of Protein Sciences Corporation's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Influenza is the condition Protein Sciences Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Influenza trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Protein Sciences Corporation pipeline card: 12 registered trials from official public datasets.Report a data error.